Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0502)

15. srpna 2017 aktualizováno: National Cancer Institute (NCI)

A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors

This randomized phase III trial studies imatinib mesylate and bevacizumab to see how well they work compared to imatinib mesylate alone in treating patients with gastrointestinal stromal tumor that has spread to other parts of the body or cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether imatinib mesylate and bevacizumab are more effective than imatinib mesylate alone in treating gastrointestinal stromal tumor.

Přehled studie

Postavení

Ukončeno

Podmínky

Intervence / Léčba

Detailní popis

PRIMARY OBJECTIVES:

I. To determine whether treatment with imatinib (imatinib mesylate) plus bevacizumab leads to improved progression free survival (PFS) versus treatment with imatinib alone in first-line treatment of incurable gastrointestinal stromal tumor (GIST).

SECONDARY OBJECTIVES:

I. To compare response probabilities (confirmed and unconfirmed complete response [CR] and partial response [PR] for subset of patients with measurable disease), overall survival, and central-review based progression-free survival (CRb-PFS) in patients treated with imatinib and bevacizumab versus those treated with imatinib alone.

II. To compare the frequency and severity of toxicities associated with imatinib plus bevacizumab versus imatinib alone.

TERTIARY OBJECTIVES:

I. To explore the association between soluble vascular endothelial growth factor (VEGF), VEGF-factor D (VEGF-D), VEGF receptor (VEGFR)-1, VEGFR-2, angiopoietin-2 (Ang-2), platelet-derived growth factor receptor (PDGFR)-AA and PDGFR-BB levels, positron emission tomography (PET) imaging and immunohistochemistry for cyclin-dependent kinase inhibitor 2A (p16), VEGF and VEGFR, with kinase mutation status and clinical outcomes.

II. To explore imatinib pharmacokinetics with single nucleotide polymorphisms involving the adenosine triphosphate (ATP)-binding cassette, sub-family G (WHITE), member 2 (ABCG2) and cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) genes, as well as other genes that are reported to influence the absorption, distribution, metabolism and elimination of imatinib.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (CLOSED TO ACCRUAL 10/1/2009): Patients receive imatinib mesylate orally (PO) once daily (QD) on days 1-21 and bevacizumab intravenously (IV) over 30-90 minutes on day 1.

ARM II (CLOSED TO ACCRUAL 10/1/2009): Patients receive imatinib mesylate PO QD on days 1-21.

In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 1 month, every 6 months for 2 years, and then annually for 5 years.

Typ studie

Intervenční

Zápis (Aktuální)

12

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
        • Tom Baker Cancer Centre
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 4E6
        • BCCA-Vancouver Cancer Centre
  • Spojené státy
    • California
      • Berkeley, California, Spojené státy, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Burlingame, California, Spojené státy, 94010
        • Mills - Peninsula Hospitals
      • Greenbrae, California, Spojené státy, 94904
        • Marin General Hospital
      • Los Angeles, California, Spojené státy, 90033
        • USC / Norris Comprehensive Cancer Center
      • Novato, California, Spojené státy, 94945
        • Sutter Cancer Research Consortium
      • San Francisco, California, Spojené státy, 94118
        • California Pacific Medical Center-Pacific Campus
      • Vallejo, California, Spojené státy, 94589
        • Sutter Solano Medical Center/Cancer Center
    • District of Columbia
      • Washington, D.C., District of Columbia, Spojené státy, 20007
        • MedStar Georgetown University Hospital
    • Georgia
      • Columbus, Georgia, Spojené státy, 31904
        • John B Amos Cancer Center
      • Savannah, Georgia, Spojené státy, 31404
        • Memorial University Medical Center
      • Valdosta, Georgia, Spojené státy, 31603
        • South Georgia Medical Center
    • Illinois
      • Aurora, Illinois, Spojené státy, 60504
        • Rush - Copley Medical Center
      • Chicago, Illinois, Spojené státy, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Spojené státy, 60631
        • Presence Resurrection Medical Center
      • Decatur, Illinois, Spojené státy, 62526
        • Decatur Memorial Hospital
      • Joliet, Illinois, Spojené státy, 60435
        • Joliet Oncology-Hematology Associates Limited
      • La Grange, Illinois, Spojené státy, 60525
        • Adventist La Grange Memorial Hospital
      • Naperville, Illinois, Spojené státy, 60540
        • Edward Hospital/Cancer Center
      • Springfield, Illinois, Spojené státy, 62781
        • Memorial Medical Center
      • Urbana, Illinois, Spojené státy, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Spojené státy, 61801
        • Carle Clinic-Urbana Main
    • Indiana
      • Beech Grove, Indiana, Spojené státy, 46107
        • Franciscan St. Francis Health-Beech Grove
      • Michigan City, Indiana, Spojené státy, 46360
        • Franciscan Saint Anthony Health-Michigan City
      • Richmond, Indiana, Spojené státy, 47374
        • Reid Hospital and Health Care Services
    • Iowa
      • Ames, Iowa, Spojené státy, 50010
        • McFarland Clinic PC-William R Bliss Cancer Center
      • Clive, Iowa, Spojené státy, 50325
        • Medical Oncology and Hematology Associates-West Des Moines
      • Davenport, Iowa, Spojené státy, 52803
        • Genesis Medical Center - East Campus
      • Davenport, Iowa, Spojené státy, 52804
        • Genesis Medical Center - West Campus
      • Des Moines, Iowa, Spojené státy, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Spojené státy, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Spojené státy, 50309
        • Medical Oncology and Hematology Associates-Des Moines
      • Des Moines, Iowa, Spojené státy, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, Spojené státy, 50314
        • Medical Oncology and Hematology Associates-Laurel
      • Des Moines, Iowa, Spojené státy, 50307
        • Mercy Capitol
      • Des Moines, Iowa, Spojené státy, 50309
        • Iowa Oncology Research Association CCOP
      • Sioux City, Iowa, Spojené státy, 51101
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, Spojené státy, 51104
        • Saint Luke's Regional Medical Center
      • Sioux City, Iowa, Spojené státy, 51104
        • Mercy Medical Center-Sioux City
    • Kansas
      • Chanute, Kansas, Spojené státy, 66720
        • Cancer Center of Kansas - Chanute
      • Dodge City, Kansas, Spojené státy, 67801
        • Cancer Center of Kansas - Dodge City
      • El Dorado, Kansas, Spojené státy, 67042
        • Cancer Center of Kansas - El Dorado
      • Fort Scott, Kansas, Spojené státy, 66701
        • Cancer Center of Kansas - Fort Scott
      • Independence, Kansas, Spojené státy, 67301
        • Cancer Center of Kansas-Independence
      • Kingman, Kansas, Spojené státy, 67068
        • Cancer Center of Kansas-Kingman
      • Lawrence, Kansas, Spojené státy, 66044
        • Lawrence Memorial Hospital
      • Newton, Kansas, Spojené státy, 67114
        • Cancer Center of Kansas - Newton
      • Parsons, Kansas, Spojené státy, 67357
        • Cancer Center of Kansas - Parsons
      • Pratt, Kansas, Spojené státy, 67124
        • Cancer Center of Kansas - Pratt
      • Salina, Kansas, Spojené státy, 67401
        • Salina Regional Health Center
      • Salina, Kansas, Spojené státy, 67401
        • Cancer Center of Kansas - Salina
      • Wellington, Kansas, Spojené státy, 67152
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, Spojené státy, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Spojené státy, 67208
        • Associates In Womens Health
      • Wichita, Kansas, Spojené státy, 67214
        • Cancer Center of Kansas - Main Office
      • Wichita, Kansas, Spojené státy, 67214
        • Via Christi Regional Medical Center
      • Wichita, Kansas, Spojené státy, 67214
        • Wichita CCOP
      • Winfield, Kansas, Spojené státy, 67156
        • Cancer Center of Kansas - Winfield
    • Michigan
      • Adrian, Michigan, Spojené státy, 49221
        • Bixby Medical Center
      • Adrian, Michigan, Spojené státy, 49221
        • Hickman Cancer Center
      • Ann Arbor, Michigan, Spojené státy, 48106-0995
        • Saint Joseph Mercy Hospital
      • Ann Arbor, Michigan, Spojené státy, 48106
        • Michigan Cancer Research Consortium CCOP
      • Dearborn, Michigan, Spojené státy, 48124
        • Oakwood Hospital and Medical Center
      • Detroit, Michigan, Spojené státy, 48236
        • Saint John Hospital and Medical Center
      • Flint, Michigan, Spojené státy, 48502
        • Hurley Medical Center
      • Flint, Michigan, Spojené státy, 48532
        • Genesys Regional Medical Center-West Flint Campus
      • Jackson, Michigan, Spojené státy, 49201
        • Allegiance Health
      • Lansing, Michigan, Spojené státy, 48912
        • Sparrow Hospital
      • Livonia, Michigan, Spojené státy, 48154
        • Saint Mary Mercy Hospital
      • Monroe, Michigan, Spojené státy, 48162
        • Mercy Memorial Hospital
      • Monroe, Michigan, Spojené státy, 48162
        • Toledo Clinic Cancer Centers-Monroe
      • Pontiac, Michigan, Spojené státy, 48341
        • Saint Joseph Mercy Oakland
      • Port Huron, Michigan, Spojené státy, 48060
        • Saint Joseph Mercy Port Huron
      • Saginaw, Michigan, Spojené státy, 48601
        • Saint Mary's of Michigan
      • Saint Joseph, Michigan, Spojené státy, 49085
        • Oncology Care Associates PLLC
      • Southfield, Michigan, Spojené státy, 48075
        • Providence Hospital-Southfield Cancer Center
      • Warren, Michigan, Spojené státy, 48093
        • Saint John Macomb-Oakland Hospital
    • Minnesota
      • Duluth, Minnesota, Spojené státy, 55805
        • Essentia Health Cancer Center
      • Duluth, Minnesota, Spojené státy, 55805
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Spojené státy, 55805
        • Miller-Dwan Hospital
      • Hutchinson, Minnesota, Spojené státy, 55350
        • Hutchinson Area Health Care
      • Litchfield, Minnesota, Spojené státy, 55355
        • Meeker County Memorial Hospital
      • Maplewood, Minnesota, Spojené státy, 55109
        • Saint John's Hospital - Healtheast
      • Minneapolis, Minnesota, Spojené státy, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Spojené státy, 55407
        • Virginia Piper Cancer Institute
      • Saint Paul, Minnesota, Spojené státy, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Spojené státy, 55102
        • Saint Joseph's Hospital - Healtheast
      • Shakopee, Minnesota, Spojené státy, 55379
        • Saint Francis Regional Medical Center
      • Woodbury, Minnesota, Spojené státy, 55125
        • Woodwinds Health Campus
    • Missouri
      • Springfield, Missouri, Spojené státy, 65804
        • Cancer Research for the Ozarks NCORP
      • Springfield, Missouri, Spojené státy, 65804
        • Mercy Hospital Springfield
    • Montana
      • Billings, Montana, Spojené státy, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, Spojené státy, 59101
        • Northern Rockies Radiation Oncology Center
      • Billings, Montana, Spojené státy, 59101
        • Montana Cancer Consortium CCOP
      • Billings, Montana, Spojené státy, 59102
        • Frontier Cancer Center and Blood Institute-Billings
      • Billings, Montana, Spojené státy, 59107
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Spojené státy, 59715
        • Bozeman Deaconess Hospital
      • Bozeman, Montana, Spojené státy, 59715
        • Bozeman Deaconess Cancer Center
      • Butte, Montana, Spojené státy, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, Spojené státy, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Spojené státy, 59405
        • Berdeaux, Donald MD (UIA Investigator)
      • Havre, Montana, Spojené státy, 59501
        • Northern Montana Hospital
      • Helena, Montana, Spojené státy, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Spojené státy, 59901
        • Kalispell Regional Medical Center
      • Kalispell, Montana, Spojené státy, 59901
        • Glacier Oncology PLLC
      • Kalispell, Montana, Spojené státy, 59901
        • Kalispell Medical Oncology
      • Missoula, Montana, Spojené státy, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Spojené státy, 59804
        • Guardian Oncology and Center for Wellness
      • Missoula, Montana, Spojené státy, 59801
        • Community Medical Hospital
      • Missoula, Montana, Spojené státy, 59802
        • Montana Cancer Specialists
    • New Jersey
      • Mount Holly, New Jersey, Spojené státy, 08060
        • Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County
      • Voorhees, New Jersey, Spojené státy, 08043
        • Virtua West Jersey Hospital Voorhees
    • New York
      • Buffalo, New York, Spojené státy, 14263
        • Roswell Park Cancer Institute
      • Glens Falls, New York, Spojené státy, 12801
        • Glens Falls Hospital
      • Middletown, New York, Spojené státy, 10940
        • Orange Regional Medical Center
      • Rochester, New York, Spojené státy, 14642
        • University of Rochester
      • Rochester, New York, Spojené státy, 14620
        • Highland Hospital
      • Rochester, New York, Spojené státy, 14623
        • Interlakes Foundation Inc-Rochester
    • North Carolina
      • Kinston, North Carolina, Spojené státy, 28501
        • Kinston Medical Specialists PA
    • North Dakota
      • Bismarck, North Dakota, Spojené státy, 58501
        • Sanford Bismarck Medical Center
      • Bismarck, North Dakota, Spojené státy, 58501
        • Mid Dakota Clinic
      • Bismarck, North Dakota, Spojené státy, 58501
        • Saint Alexius Medical Center
    • Ohio
      • Bowling Green, Ohio, Spojené státy, 43402
        • Toledo Clinic Cancer Centers-Bowling Green
      • Cincinnati, Ohio, Spojené státy, 45267
        • University of Cincinnati
      • Clyde, Ohio, Spojené státy, 43410
        • North Coast Cancer Care-Clyde
      • Dayton, Ohio, Spojené státy, 45406
        • Good Samaritan Hospital - Dayton
      • Dayton, Ohio, Spojené státy, 45409
        • Miami Valley Hospital
      • Dayton, Ohio, Spojené státy, 45415
        • Samaritan North Health Center
      • Dayton, Ohio, Spojené státy, 45405
        • Grandview Hospital
      • Dayton, Ohio, Spojené státy, 45420
        • Dayton CCOP
      • Dayton, Ohio, Spojené státy, 45428
        • Veteran Affairs Medical Center
      • Elyria, Ohio, Spojené státy, 44035
        • Hematology Oncology Center Incorporated
      • Findlay, Ohio, Spojené státy, 45840
        • Blanchard Valley Hospital
      • Franklin, Ohio, Spojené státy, 45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Greenville, Ohio, Spojené státy, 45331
        • Wayne Hospital
      • Kettering, Ohio, Spojené státy, 45429
        • Kettering Medical Center
      • Lima, Ohio, Spojené státy, 45804
        • Lima Memorial Hospital
      • Maumee, Ohio, Spojené státy, 43537
        • Toledo Clinic Cancer Centers-Maumee
      • Maumee, Ohio, Spojené státy, 43537
        • Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
      • Maumee, Ohio, Spojené státy, 43537
        • Saint Luke's Hospital
      • Oregon, Ohio, Spojené státy, 43616
        • Saint Charles Hospital
      • Oregon, Ohio, Spojené státy, 43616
        • Toledo Clinic Cancer Centers-Oregon
      • Sandusky, Ohio, Spojené státy, 44870
        • North Coast Cancer Care
      • Sylvania, Ohio, Spojené státy, 43560
        • Flower Hospital
      • Tiffin, Ohio, Spojené státy, 44883
        • Mercy Hospital of Tiffin
      • Toledo, Ohio, Spojené státy, 43608
        • Saint Vincent Mercy Medical Center
      • Toledo, Ohio, Spojené státy, 43623
        • Toledo Clinic Cancer Centers-Toledo
      • Toledo, Ohio, Spojené státy, 43614
        • University of Toledo
      • Toledo, Ohio, Spojené státy, 43617
        • Toledo Community Hospital Oncology Program CCOP
      • Toledo, Ohio, Spojené státy, 43606
        • The Toledo Hospital/Toledo Children's Hospital
      • Toledo, Ohio, Spojené státy, 43623
        • Mercy Saint Anne Hospital
      • Troy, Ohio, Spojené státy, 45373
        • Upper Valley Medical Center
      • Wauseon, Ohio, Spojené státy, 43567
        • Fulton County Health Center
      • Wilmington, Ohio, Spojené státy, 45177
        • Clinton Memorial Hospital
      • Xenia, Ohio, Spojené státy, 45385
        • Greene Memorial Hospital
    • Oregon
      • Portland, Oregon, Spojené státy, 97216
        • Adventist Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19111
        • Fox Chase Cancer Center
      • Wilkes-Barre, Pennsylvania, Spojené státy, 18765
        • Geisinger South Wilkes-Barre
    • South Dakota
      • Rapid City, South Dakota, Spojené státy, 57701
        • Rapid City Regional Hospital
    • Texas
      • San Antonio, Texas, Spojené státy, 78229
        • University Hospital
      • San Antonio, Texas, Spojené státy, 78229
        • University of Texas Health Science Center at San Antonio
      • San Antonio, Texas, Spojené státy, 78209
        • Audie L Murphy Veterans Affairs Hospital
    • Virginia
      • Fredericksburg, Virginia, Spojené státy, 22401
        • Fredericksburg Oncology Inc
    • Washington
      • Bellingham, Washington, Spojené státy, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Bremerton, Washington, Spojené státy, 98310
        • Harrison HealthPartners Hematology and Oncology-Bremerton
      • Kennewick, Washington, Spojené státy, 99336
        • Kadlec Clinic Hematology and Oncology
      • Seattle, Washington, Spojené státy, 98195
        • University of Washington Medical Center
      • Seattle, Washington, Spojené státy, 98109
        • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      • Seattle, Washington, Spojené státy, 98104
        • Harborview Medical Center
      • Seattle, Washington, Spojené státy, 98104
        • Minor and James Medical PLLC
      • Seattle, Washington, Spojené státy, 98112
        • Group Health Cooperative-Seattle
      • Seattle, Washington, Spojené státy, 98122-4307
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Spojené státy, 98122
        • The Polyclinic
      • Seattle, Washington, Spojené státy, 98112
        • Group Health Cooperative of Puget Sound Oncology Consortium
      • Spokane, Washington, Spojené státy, 99202
        • Cancer Care Northwest - Spokane South
      • Wenatchee, Washington, Spojené státy, 98801
        • Wenatchee Valley Hospital and Clinics
    • West Virginia
      • Charleston, West Virginia, Spojené státy, 25304
        • West Virginia University Charleston
    • Wisconsin
      • Chippewa Falls, Wisconsin, Spojené státy, 54729
        • Marshfield Clinic-Chippewa Center
      • Eau Claire, Wisconsin, Spojené státy, 54701
        • Marshfield Clinic Cancer Center at Sacred Heart
      • Eau Claire, Wisconsin, Spojené státy, 54701
        • Sacred Heart Hospital
      • Marshfield, Wisconsin, Spojené státy, 54449
        • Marshfield Clinic
      • Marshfield, Wisconsin, Spojené státy, 54449
        • Saint Joseph's Hospital
      • Minocqua, Wisconsin, Spojené státy, 54548
        • Marshfield Clinic-Minocqua Center
      • Rhinelander, Wisconsin, Spojené státy, 54501
        • Marshfield Clinic at James Beck Cancer Center
      • Rice Lake, Wisconsin, Spojené státy, 54868
        • Marshfield Clinic-Rice Lake Center
      • Stevens Point, Wisconsin, Spojené státy, 54481
        • Saint Michael's Hospital
      • Wausau, Wisconsin, Spojené státy, 54401
        • Marshfield Clinic-Wausau Center
      • Weston, Wisconsin, Spojené státy, 54476
        • Diagnostic and Treatment Center
      • Weston, Wisconsin, Spojené státy, 54476
        • Marshfield Clinic - Weston Center
      • Wisconsin Rapids, Wisconsin, Spojené státy, 54494
        • Marshfield Clinic - Wisconsin Rapids Center
    • Wyoming
      • Sheridan, Wyoming, Spojené státy, 82801
        • Welch Cancer Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • REGISTRATION # 1
  • Patient must have a biopsy proven diagnosis of gastrointestinal stromal tumor (GIST) that is distantly metastatic or unresectable; patients must be determined to be unresectable for cure
  • Patient may have measurable and/or non-measurable disease; computed tomography (CT) or magnetic resonance imaging (MRI) used for measurable disease must have been completed within 28 days prior to registration; CT or MRI used for non-measurable disease must have been completed within 42 days prior to registration; PET scans are not sufficient for disease assessment; all disease must be assessed and documented on the Baseline Tumor Assessment Form
  • CT/MRI scans must be performed and submitted for central review; archived tissue must be submitted as outlined
  • Institutions must seek additional patient consent for PET scans as outlined; if patient consents to the submission of PET scans, the patient must also be registered to Registration #2
  • Patient must not have known brain metastasis
  • Patient must have a Zubrod performance status of 0 - 3
  • Patient must have resolution of transient toxicities from any prior chemotherapy, radiation therapy or surgery to =< grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)
  • Patient may have previously received traditional chemotherapeutic agents in any setting, provided at least 28 days have elapsed since completing chemotherapy and they have recovered to =< grade 1 from all drug-induced toxicities

  • Patient must not have received prior treatment with bevacizumab or other agents targeting VEGF, VEGFR, or PDGFR for advanced disease; those agents may have been used in the adjuvant setting if the patient did not recur for at least 12 months following the completion of treatment; patients may be receiving imatinib for advanced disease prior to registration provided they meet ALL of the following criteria:

    • Patient must not have received more than 30 days of imatinib treatment prior to registration
    • Patients have not been restaged; (baseline disease assessments prior to initiation of imatinib must fulfill requirements)
    • Patients must have no clinical signs of progression
  • Prior radiotherapy is allowed, provided at least 28 days have elapsed since the last treatment and there is evidence of progressive disease within the radiation field or disease outside the radiation field
  • Patient must not have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration, or anticipation of need for major surgical procedure during the course of the study; no fine needle aspirations or core biopsies are allowed within 7 days prior to registration; no procedure to place a port-a-cath is allowed within 7 days prior to registration
  • Patient must have a total bilirubin =< 2.0 x institutional upper limit of normal (IULN), obtained within 28 days prior to registration
  • Patients without liver involvement must have serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2.5 x IULN, obtained within 28 days prior to registration; patients with liver involvement must have SGOT or SGPT =< 5 x IULN
  • Patient must have adequate renal function as defined by a serum creatinine =< 1.5 x IULN obtained within 28 days prior to registration
  • Patient must have urine protein/creatinine ratio (UPC) < 1; this result must be obtained within 28 days prior to registration
  • Patient must have an absolute neutrophil count (ANC) >= 1,000/mcl obtained within 28 days prior to registration
  • Patient must have a platelet count >= 100,000/mcl obtained within 28 days prior to registration
  • Patient must have hemoglobin >= 9 gm/dl (this may be achieved by transfusion if needed) obtained within 28 days prior to registration
  • Patient must have an international normalized ratio (INR) =< 1.5, obtained within 28 days prior to registration
  • Patient must have a partial thromboplastin time (PTT) =< IULN, obtained within 28 days prior to registration
  • Patient must not be taking therapeutic doses of Coumadin (warfarin) as anticoagulation at the time of registration; patients requiring therapeutic anticoagulation may use low-molecular weight heparin (e.g., Lovenox) or other agents, and mini-dose Coumadin (1 mg PO QD) as prophylaxis is allowed
  • Patient must not have had a cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction or unstable angina within 6 months prior to registration; patient must not have serious cardiac arrhythmia requiring medication, New York Heart Association (NYHA) class II or greater congestive heart failure, or clinically significant peripheral vascular disease
  • Patient must not have had an abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to registration
  • Patient must not plan to use other investigational agents while on protocol treatment
  • Patient must have no contraindication to oral medications (e.g., severe dysphagia); patients with gastrostomy (G)- or jejunostomy (J)- tubes are eligible
  • Patient must not have blood pressure > 160/90; patients with a history of hypertension must be on a stable regimen of anti-hypertensive therapy
  • Patient must not have a serious, non-healing wound, ulcer, or bone fracture
  • Patient must not be pregnant or nursing; male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout protocol treatment and for up to 6 months following discontinuation of study drugs
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
  • If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day; in calculating days of tests and measurements, the day a test or measurement is done is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks later would be considered day 28
  • All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • At the time of patient registration, the treating institution's name and identification (ID) number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base
  • REGISTRATION #2 - PET SUBSTUDY:
  • Patient must have been registered to the main study
  • Patient must have consented to the submission of PET scans

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)
Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Jiný: Laboratorní analýza biomarkerů
Korelační studie
Jiný: Farmakologická studie
Korelační studie
Biologický: Bevacizumab
Vzhledem k tomu, IV
Ostatní jména:
  • Avastin
  • Anti-VEGF
  • Anti-VEGF humanizovaná monoklonální protilátka
  • Anti-VEGF rhuMAb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Imunoglobulin G1 (lidský-myší monoklonální rhuMab-VEGF gama-řetězcový anti-lidský vaskulární endoteliální růstový faktor), disulfid s lidským-myším monoklonálním lehkým řetězcem rhuMab-VEGF, dimer
  • Rekombinantní humanizovaná anti-VEGF monoklonální protilátka
  • rhuMab-VEGF
Lék: Imatinib mesylát
Vzhledem k PO
Ostatní jména:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
Aktivní komparátor: Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)
Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Jiný: Laboratorní analýza biomarkerů
Korelační studie
Jiný: Farmakologická studie
Korelační studie
Lék: Imatinib mesylát
Vzhledem k PO
Ostatní jména:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression Free Survival
Časové okno: Up to 7 years
From date of registration (defined as date of randomization) to date of first observation of progressive disease, death due to any cause or symptomatic deterioration. Patients last known to be alive and progression free are censored at last date of contact. Progression is defined as one or more of the following: 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy), provided at least one target lesion does NOT demonstrate uniform hypoattenuation over > 90% of maximal cross sectional area; unequivocal progression of non-measurable disease; appearance of new lesion/site that is not uniformly hypoattenuating; a hyperattenuating region within a previously cystic/uniformly hypoattenuating lesion will be considered progressive disease if hyperattenuating region is either >= 1 cm in longest diameter or round/oval and forms acute margins with border of target lesion; death due to disease.
Up to 7 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Response Rate
Časové okno: Up to 7 years
Confirmed response (CR) is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response (PR) is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.
Up to 7 years
Overall Survival
Časové okno: up to 7 years
From date of registration (defined as date of randomization) to date of death due to any cause. Patients last known to be alive are censored at last date of contact. Note: median was not reached in the Imatinib arm due to limited follow-up data.
up to 7 years
Central-review Based Progression-free Survival (CRb-PFS)
Časové okno: up to 7 years
From date of registration (defined as date of randomization) to date of first documentation of one of the following events: death; first documentation of progression based on central review of the appropriate computed tomography (CT) or magnetic resonance imaging (MRI) scans; development of new lesions or disease not identified on CT or MRI; or symptomatic deterioration. Patients not experiencing any of these events will be censored at last date of contact.
up to 7 years
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
Časové okno: Up to 7 years
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Up to 7 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

National Cancer Institute (NCI)

Vyšetřovatelé

  • Vrchní vyšetřovatel: Charles Blanke, Southwest Oncology Group

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. dubna 2008

Primární dokončení (Aktuální)

1. července 2015

Dokončení studie (Aktuální)

1. července 2015

Termíny zápisu do studia

První předloženo

10. května 2006

První předloženo, které splnilo kritéria kontroly kvality

10. května 2006

První zveřejněno (Odhad)

11. května 2006

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

14. září 2017

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

15. srpna 2017

Naposledy ověřeno

1. srpna 2017

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • NCI-2009-00776 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
  • U10CA032102 (Grant/smlouva NIH USA)
  • U10CA180888 (Grant/smlouva NIH USA)
  • CDR0000482236
  • S0502 (CTEP)

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Gastrointestinální stromální nádor

Klinické studie na Laboratorní analýza biomarkerů

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Dominican Republic

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit